Overview

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the efficacy and safety of RGN-137 topical gel with that of placebo gel for treatment of junctional epidermolysis bullosa (JEB) or dystrophic epidermolysis bullosa (DEB).
Phase:
Phase 2
Details
Lead Sponsor:
Lenus Therapeutics, LLC